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Abstract
Purpose: Human pluripotent stem cell (hPSC)-derived dopaminergic neuron progenitor cells
(DAPCs) are a potential therapy for Parkinson’s disease (PD). However, their intracranial
administration raises safety concerns including uncontrolled proliferation, migration and
inflammation. Here, we apply a bimodal imaging approach to investigate the fate of DAPC
transplants in the rat striatum.
Procedures: DAPCs co-expressing luciferase and ZsGreen or labelled with micron-sized particles
of iron oxide (MPIOs) were transplanted in the striatum of RNU rats (n = 6 per group). DAPCs were
tracked in vivo using bioluminescence and magnetic resonance (MR) imaging modalities.
Results: Transgene silencing in differentiating DAPCs accompanied with signal attenuation due
to animal growth rendered the bioluminescence undetectable by week 2 post intrastriatal
transplantation. However, MR imaging of MPIO-labelled DAPCs showed that transplanted cells
remained at the site of injection for over 120 days. Post-mortem histological analysis of DAPC
transplants demonstrated that labelling with either luciferase/ZsGreen or MPIOs did not affect
the ability of cells to differentiate into mature dopaminergic neurons. Importantly, labelled cells
did not elicit increased glial reactivity compared to non-labelled cells.
Conclusions: In summary, our findings support the transplantation of hPSC-derived DAPCs as a
safe treatment for PD.
Key words: Dopaminergic neuron progenitor cells, Human pluripotent stem cell, Parkinson’s
disease, Non-invasive imaging, Bioluminescence, Magnetic resonance imaging
Introduction
Parkinson’s disease (PD) is a neurodegenerative disease that
results in part from the progressive loss of dopaminergic
(DA) neurons in the substantia nigra. Several groups have
shown that human pluripotent stem cell (hPSC)-derived
dopaminergic neuron progenitor cells (DAPCs) can generate
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mature DA neurons and improve motor function following
intrastriatal transplantation in animal models of PD [1, 2].
This has now evolved to the point that the first in human
hPSC-based DA neural transplants are being undertaken or
planned in patients with PD. However, prior to undertaking
larger-scale clinical studies, animal experiments are needed
to adequately assess the safety of the therapies. Key safety
concerns with such therapies for PD and other central
nervous system (CNS) disorders include the risk that the
implanted cells could proliferate and form space-occupying
masses and/or migrate to off-target sites within the CNS and/
or induce major neuroinflammation [3]. In addition to
considering the potential risks, it is also important to monitor
the long-term viability and differentiation capacity of
implanted cells, as to be effective, they must differentiate
into the appropriate phenotype and persist in the brain.
An effective strategy for monitoring the proliferation,
viability and localisation of implanted cells longitudinally
is to employ a non-invasive imaging approach compris-
ing different modalities, such as bioluminescence (BLI),
magnetic resonance (MRI) and fluorescence imaging [4,
5]. BLI is the most sensitive live animal imaging
technique, enabling relatively small numbers of
transplanted cells to be detected [6]. This technique
requires that the cells express a luciferase reporter, which
means that a signal is only emitted if the cells are alive.
An increase in BLI signal over time indicates cell
proliferation and potential tumour formation whereas a
loss of signal suggests that the cells are no longer viable.
A drawback with BLI, however, is that spatial resolution
is poor, which means that it cannot be used to determine
the location of the implanted cells and/or any resultant
masses within the brain. MR imaging, on the other hand,
has a very high spatial resolution and can accurately map
the position of intracranial lesions [7]. Moreover, by
labelling cells prior to administration with an appropriate
contrast agent, such as iron oxide particles [8] or 19F-
based tracking agents [9], MRI can be used to plot the
biodistribution of the cells over time.
Hoehn and co-workers have shown previously that BLI
and MR imaging can be used to monitor the viability and
intracranial biodistribution of human embryonic stem cell
(hESC)-derived neural stem cells following implantation
into the mouse striatum [10]. To the best of our knowledge,
this bimodal approach has not previously been used to track
the tumourigenicity, viability and biodistribution of hESC-
derived DAPCs, following intrastriatal administration into
the rat brain. A key aim of this study, therefore, was to
assess the potential of this bimodal BLI/MR strategy to track
hESC-derived DAPCs in vivo. In addition to evaluating the
effectiveness of the imaging modalities themselves, we also
investigated whether the labels used for tracking (i.e. a
firefly luciferase, Fluc-ZsGreen bicistronic vector for BLI
and iron oxide particles for MR imaging [4, 11]) affected the
differentiation potential of the cells and/or their immunoge-
nicity following implantation into the rat striatum.
Materials and Methods
hESC Culture and Maintenance
The clinical-grade RC17 hESC line was obtained from
Roslin Cells Ltd., UK. Cells were expanded on laminin 521
(0.5 μg/cm2) (Biolamina) in iPS-Brew XF (StemMACS™).
Cells were passaged as small clumps using Versene, a non-
enzymatic cell dissociation reagent (ThermoFisher Scien-
tific), and 10 μM of Rho kinase (Rock) inhibitor Y-27632
dihydrochloride (StemMACS, Miltenyi) was added to the
medium for the first 24 h after plating. The medium was
changed daily, and cells were maintained at 37 °C under 5 %
CO2.
Generation of hESC Reporter Line and Labelling
with Iron Oxide Particles
RC17 cells were transduced with a lentiviral vector encoding
for the bicistronic expression of the codon-optimised firefly
luciferase (luc2) and ZsGreen (via an IRES link) under the
constitutive promoter elongation factor-α (EF1α). The vector
plasmid was a gift from Bryan Welm (Addgene plasmid
#39196), and the production and titration of viral particles
was carried out using established protocols [11]. In order to
transduce the hESCs, colonies of undifferentiated RC17
cells were dissociated into very small clumps consisting of
about 10–15 cells using Versene for 5 min. After centrifu-
gation, the cells were counted and seeded onto laminin
521 at a density of approximately 2.5 × 104 cells/cm2 in the
presence of 10 μM Y-27632. Cells were incubated overnight
and transduced on the following day with 25 × 104 viral
particles (multiplicity of infection of approximately 5) in the
presence of polybrene (10 μg/ml). After 24 h, the medium
was replaced, and the cells were expanded for 4 days prior to
sorting for ZsGreen expression with a BD FACSAria (BD
Biosciences) flow sorter. The Fluc-ZsGreen+ cells were
collected in iPS-Brew culture medium supplemented with
10 μM Y-27632, seeded on laminin 521 and expanded for
subsequent experiments. To assess bioluminescence activity,
cells were plated at different densities in black 96-well plates
(Thermo Scientific), allowed to settle for 2–4 h and then
incubated with medium containing D-luciferin (150 μg/ml,
Promega) prior to data acquisition with an IVIS spectrum
system (Perkin Elmer).
Micron-sized particles of iron oxide (MPIO) were used as
a label for MR detection of DAPCs. Suncoast Yellow
MPIOs (Bangs Beads, 1.63 μm nominal diameter, Bangs
Laboratories, Inc.) were added directly to the DAPC’s cell
culture medium at a concentration of approximately 1500
particles/μl for 24 h. After the labelling period, cells were
carefully washed with PBS to remove unbound particles,
harvested and then used for in vivo studies. The extent of
MPIO labelling was assessed with a FACSCalibur (BD
Biosciences) flow cytometer.
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Differentiation into Neural Precursors and
Mature Neurons
RC17 cells were differentiated towards mesencephalic
DAPCs or terminally differentiated into mature DA neurons
as previously described [12]. In brief, DAPCs are obtained
after neuralisation, patterning and expansion of the cells for
a period of 16 days whereas DA neurons are obtained via the
maturation of DAPCs for 34 days. Correct caudalization of
progenitors towards a midbrain fate was achieved using
0.9 μM GSK3 inhibitor (CHIR99021).
Cell Implantation and In Vivo Imaging
RNU rats (males, 5–6 weeks old) were purchased from
Charles River and housed in individually ventilated cages
under a 12-h light/dark cycle with ad libitum access to
standard food and water. All animal experiments were
performed under a licence granted through the UK Animals
(Scientific Procedures) Act 1986 and were approved by the
University of Liverpool ethics committee. All applicable
institutional and/or national guidelines for the care and use
of animals were followed. All procedures (surgical admin-
istration of cells and imaging) were carried out under
isoflurane anaesthesia.
Single-cell suspensions prepared in Hanks’ Balanced Salt
Solution were implanted stereotactically into the left and
right hemispheres of the rats’ brains. Using the bregma as a
reference, the skull was drilled at 0 mm anteroposterior and
±1.5 mm mediolateral, with each hemisphere receiving two
deposits of cells at a depth of −5.0 and −4.3 mm from the
dura. Each deposit contained 75 × 103 cells in 0.75 μl of
PBS, delivered with a microsyringe connected to an infusion
pump. The rats were divided into three different experimen-
tal groups as outlined in Table 1.
BLI was carried out with an IVIS spectrum system. After
inducing anaesthesia, the rats’ heads were shaved and the
animals received an intraperitoneal injection of luciferin at a
dose of 150 mg/kg body weight. Data were acquired 20 min
post administration of the substrate with a field of view B
(6.5 cm), medium binning, f-stop 1 and exposure time
calculated automatically by the acquisition software, up to a
maximum of 5 min. All bioluminescence data were
normalised to the acquisition conditions and are displayed
as radiance (photons/s/cm2/str).
MRI data were acquired with a Bruker Avance III
console interfaced to a 9.4T magnet system (Bruker Biospec
94/20 USR). RF excitation was achieved with an 86-mm
resonator and signal detection with a four-channel phased
array receive-only rat brain coil. Once the injection site was
located using scout images, higher resolution images were
acquired with rapid acquisition with relaxation enhancement
(RARE) sequence. Following are the parameters used: echo
time (TE) = 38 ms, repetition time (TR) = 2700 ms, RARE
factor = 8, number of excitations (NEX) = 8, field of view
(FOV) = 35 × 35 mm, matrix size = 350 × 350 pixels, slices =
20, slice thickness = 500 μm.
At the experimental endpoint, the rats received an
overdose of pentobarbital and were perfused transcardially
with PBS followed by 4 % formaldehyde. The brains were
harvested, postfixed with 4 % formaldehyde, equilibrated in
30 % sucrose and cryosectioned for microscopy analysis.
RT-qPCR
Cells were washed twice with PBS, and a minimum of 5 ×
105 cells were lysed with TRI Reagent (Sigma). Total RNA
was extracted according to the manufacturer’s protocol, and
a NanoDrop was used to determine RNA concentration. To
synthesise cDNA, RNA was treated with DNase1 and
reverse transcribed using random hexamers (Qiagen) and
Superscript III reverse transcriptase (Invitrogen). PCR was
performed on a CFX Connect system (Bio-Rad) using
SYBR Green JumpStart Taq Ready Mix (Sigma). The genes
OTX2, FOXA2 and LMX1A were measured to assess
differentiation into DAPCs, with GAPDH being used as a
housekeeping gene. Undifferentiated hESCs were used as a
control. Relative expression levels of target genes between
control and experimental samples were calculated using the
2−ΔΔCt method [13]. Primer sequences are shown in ESM
Table 1.
Immunostaining and Histology
Cells were fixed with 4 % formaldehyde for 20 min,
permeabilised with 0.1 % Triton X-100 for 20 min and
blocked with 1 % bovine serum albumin (BSA) for 30 min.
Cryosections (10 μm) from fixed tissues were permeabilised
and blocked as described above. Primary antibodies were
diluted in 1:1 Triton X-100:BSA according to the dilution
factors in ESM Table 2 and incubated for 24 h at 4 °C.
Secondary antibodies were diluted 1:1000 in 1:1 Triton
X-100:BSA and incubated for 2 h at room temperature. For
immunofluorescence, cells were counterstained with DAPI.
Images were acquired on a 3i spinning disk confocal
microscope CSU-X1 (Intelligent Imaging Innovations) and
processed with ImageJ [14]. For immunohistochemistry,
tissue sections were incubated with 1.4 mM 3,3′-diamino-
benzidine (DAB) and 0.01 % hydrogen peroxide for 15 min,
and images were acquired with a Leica DM IL microscope.
Results
hESC Labelling Does Not Negatively Impact on
Differentiation Towards DAPCs or Mature
Dopaminergic Neurons In Vitro
Flow cytometry analysis of RC17 hESCs 4 days after viral
transduction showed that approximately 47 % of the
population expressed the reporter gene ZsGreen (ESM
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Fig. 1a, b). After sorting, a pure population of hESCs
expressing the reporter was obtained (Fig. 1a, b), herein
defined as Fluc-ZsGreen+ hESCs. Fluc-ZsGreen+ hESCs
maintained expression of ZsGreen over multiple passages
and were morphologically indistinguishable from non-
transduced cells (Fig. 1a, b). To assess whether the
introduction of the reporter affected pluripotency, embryoid
bodies (EB) were generated and immunostained for markers
of embryonic germ layer derivatives. The presence of
GATA6 (endoderm), Brachyury (mesoderm) and Nestin
(ectoderm) confirmed that the Fluc-ZsGreen+ hESCs
remained pluripotent (ESM Fig. 1c).
DAPCs were assessed for the co-expression of the key
markers FOXA2, LMX1A and OTX2 on day 16 of
differentiation. Quantification of mRNA via RT-qPCR
revealed significant upregulation of all these markers
(Fig. 1c), which was confirmed via immunofluorescence
(Fig. 1d). However, fluorescence microscopy also revealed
that not all cells expressed ZsGreen after differentiation into
DAPCs (Fig. 1d). DAPCs were further differentiated into
mature DA neurons and immunostained (differentiation
day 50) to detect the classic DA neuron marker, tyrosine
hydroxylase (TH). Immunofluorescence demonstrated that
the transduced RC17-derived DA neurons expressed TH
(Fig. 1e), but ZsGreen was no longer detectable at this
differentiation stage.
Flow cytometric analysis of DAPCs showed that only 51 %
of these cells expressed ZsGreen, implying a significant loss of
reporter gene expression when compared to undifferentiated
hESCs (Fig. 1f), and complete loss once the cells had matured
to dopaminergic neurons (DAs) (Fig. 1e). Measurement of the
light output (bioluminescence) revealed that the expression of
luciferase corresponded to that of ZsGreen; that is, biolumi-
nescence was strong before differentiation (37 p/s/cell),
significantly reduced as cells differentiated towards DAPCs
(17 p/s/cell) and extremely weak when they became mature
DAs (G1 p/s/cell) (Fig. 1g).
Taken together, these results show that the introduc-
tion of the genetic reporter did not affect hESC
pluripotency nor their ability to differentiate to DAPCs
and DA neurons. However, reporter gene expression was
progressively lost as the cells differentiated towards DA
neurons. Despite the reduction in light emission in
DAPCs, we reasoned that it would still be possible to
detect them in rodents in vivo, enabling their tracking
and assessment of viability/tumourigenicity in the early
post-transplant period, but that it would not be possible
to detect the mature DA neurons.
In Vivo Imaging Reveals Absence of DAPC
Tumourigenicity and Long-Term Intracranial
Distribution
In addition to assessing the ability of BLI and MRI to detect
the implanted cells, a further objective of the in vivo studies
was to investigate whether the presence of either the Fluc-
ZsGreen reporter or the MPIOs affected (i) the
tumourigenicity of the cells, (ii) the ability of the hESC-
derived DAPCs to differentiate into mature DA neurons
in vivo or (iii) the immunogenicity of the human cells. To
this end, three groups of rats were set up. Group 1, which
served as a control group for tumour formation, comprised
of three rats that had Fluc-ZsGreen+ hESCs implanted into
the right striatum and unlabelled hESCs into the left striatum
(Fig. 2a); group 2 comprised of six rats that had DAPCs
derived from Fluc-ZsGreen+ hESCs implanted into the right
striatum and unlabelled cells into the left striatum (Fig. 2d);
group 3 comprised of six rats that had MPIO-labelled hESC-
derived DAPCs implanted into the right striatum and
unlabelled hESC-derived DAPCs implanted into the left
striatum (Fig. 4c).
hESCs and DAPCs Follow Distinct Fates In Vivo,
Irrespective of the Introduction of a Reporter
Gene
Optical imaging of animals that received undifferentiated
hESCs on the administration day and on days 14 and 27 post
administration revealed great variability in the biolumines-
cence signal. On the administration day, just one of the
animals displayed a signal, which was very weak, suggesting
that Fluc expression was not robust enough for sensitive
detection in all animals. Bioluminescence was progressively
lost from this rat but detected in a different animal at a later
time point (ESM Fig. 2a).
MR imaging of these rats at the experimental endpoint
(day 27) displayed a large area of atypical hyperintense
contrast surrounding the injection site, which was present in
both brain hemispheres of all animals (Fig. 2b and ESM
Fig. 2b). Histological analysis of the tissue showed that this
area consisted of a large number of tightly packed cells as
evidenced by strong nuclear (haematoxylin) staining in the
same area (Fig. 2b), suggesting an abnormal growth of cells.
Immunofluorescence microscopy of these samples revealed
that the masses in both hemispheres consisted of human
cells, as evidenced by positive staining for a human-specific
Table 1. Description of the experimental groups
Group Cells implanted in the left hemisphere Cells implanted in the right hemisphere Number of animals Endpoint
1 Undifferentiated hESCs Undifferentiated hESCs (Fluc-ZsGreen+) 3 Day 27
2 DAPCs DAPCs (Fluc-ZsGreen+) 6 Day 91
3 DAPCs DAPCs (MPIO-labelled) 6 Day 127
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nuclear antigen (hNuclei). Interestingly, however, not all
cells in the masses that formed in the right brain hemisphere
(Fluc-ZsGreen+ hESCs) expressed ZsGreen, suggesting that
some of the hESCs lost expression of the reporter (Fig. 2c).
The hESC-derived masses did not display a teratoma-like
tissue architecture when examined by haematoxylin and
eosin staining (data not shown). Instead, many of the cells
expressed β-III tubulin, suggesting that transplantation of
these cells in the rat brain promoted differentiation to
ectodermal lineages (ESM Fig. 2c). The growths were also
negative for OCT4, confirming that cells had differentiated
in the brain (ESM Fig. 2d). Taken together, these results
indicate that undifferentiated hESCs form mass lesions,
irrespective of the introduction of the Fluc-ZsGreen reporter.
For rats implanted with DAPCs (group 2) (Fig. 2d),
four of six animals displayed a bioluminescence signal
on the administration day (Fig. 2e and ESM Fig. 3a),
which was not detectable at the subsequent imaging
points (days 14, 28, 56 and 91). In contrast to hESCs,
administration of DAPCs resulted in no abnormal MR
contrast at the experimental endpoint (day 91, Fig. 2f),
with all animals exhibiting normal brain structures and
the needle track being the only remarkable feature.
Human cells were still present at the injection site in
both hemispheres, as evidenced by hNuclei positivity
(Fig. 3a). Importantly, the areas containing human cells
were also positive for TH, suggesting maturation of some
DAPCs in the rats’ brains within the experimental period
Fig. 1. Effect and stability of the Fluc-ZsGreen reporter gene in hESCs. a Phase contrast and fluorescence microscopy of
the control and Fluc-ZsGreen+ hESCs. Cells were imaged three passages post sorting. b ZsGreen expression, as measured via
flow cytometry, of the control and sorted hESCs. The green fluorescence of the sorted cells is stable for several passages. c
Expression of OTX2, FOXA2 and LMX1A in DAPCs obtained from Fluc-ZsGreen+ hESCs. d, e Fluorescence microscopy of
DAPCs and DAs obtained from Fluc-ZsGreen+ hESCs (differentiation days 15 and 50, respectively). Cells were immunostained
for OTX2, FOXA2, LMX1A and TH. f Flow cytometry shows that differentiation into DAPCs reduces ZsGreen expression
(approximately 47 % of the cells expressing the construct). g BLI of different numbers of Fluc-ZsGreen+ hESCs, DAPCs and
DAs and the corresponding photon flux. Data are representative of three independent experiments. Error bars represent SD,
and the solid line the linear fit of the data. Scale bars in micrographs correspond to 100 μm.
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(91 days). Not all human cells robustly expressed TH,
likely because a period of 920 weeks is necessary for the
maturation of all DAPCs. The injection sites were also
positive for a human-specific NCAM (hNCAM) antigen
(Fig. 3b), providing further evidence that human cells
had integrated with the rat brain and displayed neural
lineage commitment, irrespective of whether they had
been genetically modified.
Fig. 2. Long-term fate of hESCs and DAPCs. a Schematic of injection and experimental timeline of hESC
administration and imaging. b Representative RARE MRI scan (day 27) and corresponding histological section (H&E
staining) of a rat that received undifferentiated hESCs (left hemisphere: non-transduced, right hemisphere: Fluc-
ZsGreen+). Both sides display a large area of hyperintense contrast at the injection site (arrowheads) which was
confirmed to correspond to tightly packed cell nuclei via histology. c Fluorescence microscopy of areas of abnormal
growth in the right hemisphere. In all cases, the growth corresponded to cells of human origin, as evidenced by
expression of a human nuclear antigen. The level of ZsGreen expression was heterogeneous within the growths, with
areas of strong expression (top) and areas where ZsGreen was lost (bottom). Scale bar = 50 μm. d Schematic of
injection and experimental timeline of DAPC administration and imaging. e BLI of two of the six rats that received
DAPCs as imaged on days 1, 14 and 91. Most, but not all, rats displayed a signal on the injection day, but this was lost
by day 14, and no signal was seen at any other time points. The left panel is representative of rats that displayed signal
on day 1, and the right panel representative of rats that did not display a signal on any of the days. Data for the other
rats and time points are shown in the ESM. Note that this rat strain can display cycles of thin hair growth, as seen in
some images. f RARE MRI scans (day 90) of all six rats that received DAPCs (left hemisphere: non-transduced, right
hemisphere: Fluc-ZsGreen+). No abnormal features are seen, apart from the needle track that is still visible in some
animals (indicated arrowheads in the first rat only).
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MPIO Labelling Enables Assessment of the
Intracranial Distribution of Implanted Cells
Flow cytometry analysis of MPIO-labelled DAPCs sug-
gested that approximately 72 % of DAPCs were labelled
with the particles, as evidenced by yellow fluorescence
originating from MPIOs (Fig. 4a). We also detected a shift in
the side scatter of DAPCs after labelling with MPIOs,
providing further evidence for the internalisation of the
particles (Fig. 4b).
Rats implanted with MPIO-labelled DAPCs (group 3)
(Fig. 4c) were imaged only via MR as neither of the
hemispheres received cells with the genetic reporter.
Monitoring of this group for up to 4 months post
implantation confirmed that DAPC implantation does not
lead to tumour formation, with all rats displaying normal
brain structures at all time points. In five out of six rats,
hypointense contrast was seen in the right brain hemi-
sphere (Fig. 4d and ESM Fig. 3b). This was an expected
consequence of the MPIO labelling, which enabled us to
monitor the delivery and intracranial distribution of
DAPCs. Remarkably, the distribution of the administered
DAPCs appears to remain stable throughout the 4 months
that the animals were monitored for, with no obvious
change in the area with hypointense contrast, suggesting
that the DAPCs were confined to the areas into which they
were initially deposited. In one rat, no hypointense contrast
was observed in the target area. Further analysis of the
Fig. 3. DAPC integration with the rat brain. a Immunofluorescence microscopy of the injection sites (left hemisphere: non-
transduced, right hemisphere: Fluc-ZsGreen+). Cells express a human nuclear antigen, showing that the DAPCs survived in the
rats’ brains and expressed TH, suggesting that they matured into DAs. Arrowhead indicates a human cell strongly expressing
TH. b Immunofluorescence of a similar area but using an antibody against human NCAM as a means to confirm the human
origin of the cells. Scale bars correspond to 50 μm.
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scans revealed that for this animal, the needle had been
inserted at an angle, with the cells delivered to the
ventricle leading to them becoming lodged at a different
anatomical location (ESM Fig. 3c).
As observed before, immunofluorescence staining at the
injection sites confirmed the presence of human cells that
expressed TH, reinforcing the point that these cells were able
to integrate within the rat brain and differentiated into
mature DAs, irrespective of the MPIO labelling (Fig. 4e). In
the right hemisphere, MPIOs were found in the same areas
as the administered human cells and appeared to localise to
perinuclear regions.
Fig. 4. MPIO tracking of DAPCs in the rat brain. a Yellow fluorescence of unlabelled and MPIO-labelled DAPCs. b Forward
vs. side scatter plot of unlabelled and MPIO-labelled DAPCs. c Schematic of injection and experimental timeline of DAPC
administration and magnetic resonance imaging. d Representative RARE MRI scans of a rat that received MPIO-labelled DAPC
(left hemisphere: unlabelled, right hemisphere: labelled) as imaged on day 1, 14, 28, 42, 70 and 126 post administration.
Hypointense contrast, indicative of a reduction in relaxation time as caused by MPIO labelling, is seen in the right hemisphere
throughout the experimental period (indicated with an arrowhead in the first image). No abnormal growth is observed in either of
the hemispheres. e Immunofluorescence microscopy of the injection sites. Cells express human NCAM, showing that MPIO-
labelled DAPCs survived in the rats’ brains and TH, suggesting that DAPCs matured into DAs. MPIO-specific fluorescence is
only seen in the right hemisphere and tends to be localised near to the cell nuclei. Note that the MPIO fluorophore, Suncoast
Yellow, is also excited at 405 nm and bleeds into the DAPI channel. Scale bar = 50 μm.
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Intense Staining for GFAP Is Observed
Surrounding the Human Cell Implants
A previous study showed that the implantation of Fluc+
hESC-derived neural stem cells into the mouse striatum
caused marked glial reaction in the host brain, as evidenced
by intense immunostaining for glial fibrillary acidic protein
(GFAP), a marker of reactive astrocytes [10]. To investigate
whether Fluc-ZsGreen or MPIOs contributed to this reaction,
sections from group 2 and group 3 rats were immunostained
for GFAP. Qualitative analysis showed an increase in GFAP
staining around the human implants, but no differences in
staining intensity were observed around the implants
comprising unlabelled human cells or MPIO-labelled cells
(Fig. 5a and ESM Fig. 4a) and cells derived from Fluc-
ZsGreen+ hESCs (Fig. 5b and ESM Fig. 4b). Consistent with
the expression profile of ZsGreen in mature DA neurons
in vitro (Fig. 1e), the expression of ZsGreen in the brain
sections was barely detectable (Fig. 5b and ESM Fig. 4b).
Discussion
Our study assessed the effectiveness of BLI and MR
imaging to monitor the tumourigenicity, viability and
intracranial biodistribution of hESC-derived DAPCs follow-
ing stereotactic injection into the rat striatum. In most
animals, BLI could only detect Fluc-ZsGreen+ cells shortly
after administration and was not effective for monitoring
tumourigenicity and cell viability in the longer term. MR
imaging, on the other hand, could detect tumours arising
from undifferentiated hESCs and could monitor the intra-
cranial biodistribution of MPIO-labelled hESC-derived
DAPCs over the full time-course of our experiments.
The inability to detect cells with BLI likely resulted from
a number of factors. First, at the initial imaging session, the
rats were only 6 weeks old. During the intervening 2 weeks
before the next imaging session, the rats grew considerably
and became more pigmented (see ESM Fig. 3a), causing the
intensity of the emitted light to be reduced; this likely
explains why after day 1, bioluminescence could only be
Fig. 5. Glial reaction at the injection sites. a Immunofluorescence microscopy of brains from rats that received MPIO-
labelled DAPCs (left hemisphere: unlabelled; right hemisphere: labelled). The presence of human cells is identified with hNCAM
staining, and the intensity of GFAP staining is stronger in these areas. MPIOs are only seen in the right hemisphere. b
Immunofluorescence microscopy of brains from rats that received Fluc-ZsGreen+ DAPCs (left hemisphere: untransduced
control cells; right hemisphere Fluc-ZsGreen+ cells). Scale bars correspond to 100 μm.
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detected in a rat that had developed a large Fluc-ZsGreen+
hESC-derived mass (ESM Fig. 2a, rat 3). Bernau et al. found
that Fluc+ human foetal neuronal progenitors implanted into
the rat striatum could be imaged with BLI for 3 months [15].
However, they implanted 9 × 105 Fluc+ cells into the left
hemisphere compared with only 1.5 × 105 cells in our study.
An additional problem was that in comparison with
undifferentiated hESCs, we found that the expression levels
of the reporter genes decreased by ~50 % in Fluc-ZsGreen+
hESC-derived DAPCs and could not be detected at all in the
mature DA neurons. It is well recognised that ESC
differentiation is accompanied by increased levels of DNA
methylation, leading to gene silencing, and that the pattern
of silencing is cell type specific [16]. The choice of promoter
also affects the extent of silencing. A previous study
comparing the activity of five constitutive promoters,
EF1α, human β-actin (ACTB), cytomegalovirus (CMV),
phosphoglycerate kinase (PGK) and ubiquitinC (UbC) in
differentiating hESCs, reported that EF1α was the most
stable, with expression levels in EBs being reduced to ~50 %
of those in undifferentiated hESCs [17]. Our observation that
Fluc-ZsGreen expression was undetectable in the mature DA
neurons, both in vitro and in vivo, was unexpected.
Tennstaedt et al. have shown that a EF1α:Fluc-GFP+ neural
stem cell line derived from hESCs could be detected with
BLI for 6 weeks following injection into the mouse brain
without any noticeable decrease in bioluminescence inten-
sity [18]. However, the neural stem cells used in the
Tennstaedt study have a different phenotype to hESC-
derived DAPCs, and there is no evidence that they
differentiate into the DA lineage [18]. Likewise, there is no
evidence that the Fluc+ human foetal neuron progenitors
used in the aforementioned Bernau et al. study differentiate
into the DA lineage in the rat brain [15]. Indeed, as far as we
are aware, there are no studies that show Fluc expression in
hESC-derived DA neurons in vivo when Fluc is under the
control of a constitutive promoter. In future studies, a cell
type-specific promoter, such as FOXA2, which is expressed
in both DAPCs and mature DA neurons [19], could prove
more effective than the EF1α promoter for monitoring
viability longitudinally, especially if used with the highly
sensitive AkaLuc luciferase in combination with the sub-
strate Akalumine [20]. However, one advantage of our
system is that the loss of signal is due to differentiation. This
could be used to show that the grafted cells have indeed
followed the correct pathway post implantation rather than
dedifferentiated back into an ESC-like phenotype.
Four weeks after implantation of undifferentiated hESCs,
MR imaging could detect a cell mass in both cerebral
hemispheres, irrespective of whether the cells had been
transduced with the Fluc-ZsGreen reporter (ESM Fig. 2b).
However, no cell masses were detected at any time point
following administration of hESC-derived DAPCs, suggest-
ing that in contrast to the undifferentiated hESCs, the
DAPCs are non-tumourigenic. Cells labelled with MPIOs
could be detected at all time points using longitudinal MR
imaging. In addition, we found that the cells remained at the
injection site and did not appear to migrate to other brain
regions. From a safety perspective, the lack of migration is
important to prevent cells integrating into intact neural
circuits causing side effects (e.g. epilepsy) [21].
Previous studies have shown that labelling cells with iron
oxide nanoparticles can inhibit differentiation to specific
lineages [22, 23]. In our study, we did not find any evidence
that the bicistronic Fluc-ZsGreen reporter or the MPIOs
inhibited the differentiation of hESC-derived DAPCs into
TH+ DA neurons. The final aim of our study was to
investigate whether the reporter or the MPIOs increased glial
reactivity to the grafted cells. It is known that the
implantation of cells into the brain induces a glial response
[24], as evidenced by increased numbers of reactive GFAP+
astrocytes surrounding the grafts [10]. Transplantation of
both labelled and unlabelled DAPCs elicited a marked glial
reaction at the injection site, as expected. However, there
was no notable difference in the scale of glial response,
suggesting that neither Fluc-ZsGreen nor MPIOs increased
the glial reaction to the DAPCs [25].
Conclusions
In summary, we have demonstrated that hESC-derived
DAPCs can be labelled with luminescence and contrast-
enhancing reporters for in vivo cell tracking. Following
intracranial transplantation in the rat striatum, our findings
support the safe implementation of DAPC-derived therapies
for the treatment of PD.
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